LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

Home・Akcijų sąrašas・ANI Pharmaceuticals Inc

ANI Pharmaceuticals Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

82.02 0.06

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

80.88

Max

82.81

Pagrindiniai rodikliai
By Trading Economics
Pajamos	18M 27M
Pardavimai	16M 228M
P/E Sektoriaus vid.	50.838 77.671
Pelnas, tenkantis vienai akcijai	2.04
Pelno marža	11.684
Darbuotojai	897
EBITDA	19M 61M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+35.07% upside

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-270M 1.8B
Ankstesnė atidarymo kaina	81.96
Ankstesnė uždarymo kaina	82.02

Naujienos nuotaikos

By Acuity

27%

73%

87 / 374 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bearish Evidence

70.05 / 71.85 Palaikymas ir pasipriešinimas

ANI Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-12-10 22:02; UTC

Uždarbis

Synopsys Sees Strong 2026 as Ansys Acquisition Boosts 4Q Revenue

2025-12-10 21:46; UTC

Uždarbis

Adobe Expects Double-Digit Recurring Revenue Growth Next Year

2025-12-10 23:52; UTC

Įsigijimai, susijungimai, perėmimai

Paramount Sends Letter to Warner Bros. Shareholders Saying Its Offer Is 'Superior' -- Barrons.com

2025-12-10 23:43; UTC

Rinkos pokalbiai

Nikkei May Rise After Fed Rate Cut -- Market Talk

2025-12-10 23:36; UTC

Rinkos pokalbiai

Gold Consolidates as Traders Digest FOMC Decision -- Market Talk

2025-12-10 23:20; UTC

Uždarbis

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- 2nd Update

2025-12-10 23:15; UTC

Uždarbis

Synopsys Targets Double-Digit Growth Following Ansys Acquisition -- Interview

2025-12-10 22:59; UTC

Rinkos pokalbiai

Uždarbis

Įsigijimai, susijungimai, perėmimai

Adobe Expects Semrush Deal to Bring in New Users -- Market Talk

2025-12-10 22:45; UTC

Rinkos pokalbiai

Coca-Cola's New CEO Pick Looks A Lot Like The Last One -- Market Talk

2025-12-10 22:40; UTC

Uždarbis

Synopsys Stock Rises on Earnings Beat, Higher Guidance -- Barrons.com

2025-12-10 22:06; UTC

Įsigijimai, susijungimai, perėmimai

Paramount Sends Letter to Warner Bros. Shareholders Saying Their Offer Is 'Superior' -- Barrons.com

2025-12-10 22:06; UTC

Uždarbis

Oracle Reports Mixed Earnings. The Stock Is Falling. -- Barrons.com

2025-12-10 22:02; UTC

Uždarbis

Synopsys Stock Rises on Earnings Beat, Higher Guidance -- Barrons.com

2025-12-10 22:00; UTC

Uždarbis

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- Update

2025-12-10 21:53; UTC

Uždarbis

Adobe Earnings Show 'Rapid Adoption' of AI Tools. The Stock Is Up. -- Barrons.com

2025-12-10 21:50; UTC

Įsigijimai, susijungimai, perėmimai

Investors Bet That a Higher Bid for Warner Is Coming -- Update

2025-12-10 21:50; UTC

Rinkos pokalbiai

Uždarbis

Įsigijimai, susijungimai, perėmimai

Financial Services Roundup: Market Talk

2025-12-10 21:50; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2025-12-10 21:50; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2025-12-10 21:45; UTC

Įsigijimai, susijungimai, perėmimai

Paramount Sends Letter to Warner Bros. Shareholders Saying Their Offer Is 'Superior' -- Barrons.com

2025-12-10 21:33; UTC

Uždarbis

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- WSJ

2025-12-10 21:32; UTC

Uždarbis

Oracle Reports Mixed Earnings. The Stock Is Falling. -- Barrons.com

2025-12-10 21:28; UTC

Įsigijimai, susijungimai, perėmimai

Sverica Capital Management Announces Sale of Coastal Cloud Holdings to Tata Consultancy Services for $700M

2025-12-10 21:25; UTC

Uždarbis

Adobe Earnings Show 'Rapid Adoption' of AI Tools. The Stock Is Up. -- Barrons.com

2025-12-10 21:18; UTC

Įsigijimai, susijungimai, perėmimai

Paramount Skydance: Company Has Air Tight Financing to Deliver on Warner Bros. Offer >PSKY

2025-12-10 21:16; UTC

Uždarbis

Oracle Reports Mixed Earnings. The Stock is Falling. -- Barrons.com

2025-12-10 21:15; UTC

Įsigijimai, susijungimai, perėmimai

Paramount Skydance: Public Offer for Warner Bros. Delivers Superior Value, Faster, More Certain Path to Completion

2025-12-10 21:15; UTC

Uždarbis

Oracle: 'Sold Ampere Because We No Longer Think It Is Strategic for Us to Continue Designing, Manufacturing and Using Our Own Chips in Our Cloud Datacenters' >ORCL

2025-12-10 21:14; UTC

Uždarbis

Oracle 2Q Non-GAAP Operating Income Was $6.7 B >ORCL

2025-12-10 21:14; UTC

Uždarbis

Oracle 2Q GAAP Operating Income Was $4.7 B >ORCL

Akcijų palyginimas

Kainos pokytis

ANI Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

35.07% į viršų

12 mėnesių prognozė

Vidutinis 110.8 USD 35.07%

Aukščiausias 121 USD

Žemiausias 100 USD

Remiantis 6 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines ANI Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

6 ratings

Pirkti

Laikyti

Parduoti

Remiantis 6 analitikų, pateikusių ANI Pharmaceuticals Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

70.05 / 71.85Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

All events are bullish.

Rinkos nuotaikos

By Acuity

87 / 374 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę ANI Pharmaceuticals Inc

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.